VULM 1457

Research use only, not for human use.

VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes.

VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells.(In Vitro):Preincubation of HepG2 cells with VULM1457 (0.1 μM) significantly reduced the specific [125I]AM binding on hypoxic cells with BmaxHypox being 127±10 and KD 0.06±0.11 nM. Preincubation of cells with VULM1457 (0.1 μM) significantly enhanced the number of cells (24.2±6 %) and higher concentrations of VULM1457 (1.0 and 10.0 μM) reduces the total number of cells. In HepG2 cell lines, VULM1457 (0.03 μM; 0.1 μM) significantly down-regulated specific AM receptors on HepG2 cells, and reduced AM secretion of HepG2 cells exposed to hypoxia. VULM1457 negatively regulates cell proliferation induced by AM.(In Vivo):In male Wistar rats, VULM 1457 protected the hearts of diabetic–hypercholesterolaemic rats against ischemia/reperfusion injury in vivo. VULM 1457 (50 mg/kg/day) significantly decreases plasma total cholesterol levels (1.7±0.1 mM vs. 2.9±0.5 mM in diabetic–hypercholesterolaemic animals). The hypolipidaemic effect of VULM 1457 is also observed in the liver of DM-HCH rats (3.9±0.2 mg/g vs. 7.4±1.0 mg/g).

——

Others

Other Targets

——

——

——

228544-65-8

449.6

C25H27N3O3S

>98% (HPLC)

——

CC(C)c1cccc(C(C)C)c1NC(=O)Nc1ccc(Sc2ccc(cc2)[N+]([O-])=O)cc1

——

(-20℃)

With Ice Pack

≥ 2 years